LACTOLOGY FOUNDATION

Methylcellulose (ATC A06AC06) is a bulk-forming laxative derived from cellulose, used orally for the management of functional constipation and conditions requiring soft stools, and is generally considered compatible with breastfeeding due to minimal systemic absorption and negligible expected transfer into breast milk.e-lactation+3

Substance and ATC class

Methylcellulose is a semi-synthetic, high-molecular-weight polysaccharide obtained by methylation of cellulose, classified in the ATC system as A06AC06 (bulk-forming laxatives). It is formulated as a hydrophilic, water-swellable powder or granules for oral use, often in sachets or tablets, and may also be used as a pharmaceutical excipient and food additive because it is non-digestible, non-toxic and non-allergenic.wikipedia+3

Indications and therapeutic uses

Medicinally, methylcellulose is indicated for symptomatic treatment of constipation and for facilitating defecation in patients who benefit from softer stools, such as those with anal fissures, haemorrhoids or inflammatory conditions of the anorectal region. It is also used chronically in functional bowel disorders to normalize stool consistency (for example in irritable bowel syndrome or diverticulosis), and may be part of regimens aiming to avoid excessive straining.youtubeatcddd.fhi

Mechanism of action (pharmacodynamics)

As a bulk-forming laxative, methylcellulose acts by absorbing water in the intestinal lumen, forming a viscous, gelatinous mass that increases stool bulk and water content. This distension of the colonic contents stimulates mechanoreceptors in the intestinal mucosa, enhances peristaltic activity, and promotes more regular and less effortful defecation.drugbankyoutube

Pharmacokinetics and systemic exposure

Methylcellulose is not digested or absorbed in the gastrointestinal tract and is considered metabolically inert, passing through the gut largely unchanged. It is therefore excreted in the faeces, with negligible systemic bioavailability, a property that underlies its low potential for systemic toxicity and its generally favourable safety profile in special populations, including pregnant and lactating women.drugs+2youtube

Adverse effects and safety profile

Typical adverse reactions are related to its local gastrointestinal action and include abdominal distension, flatulence and, rarely, cramp-like pain due to rapid gas formation when bacterial fermentation occurs. Inadequate fluid intake may predispose to oesophageal or intestinal obstruction, so administration with sufficient water is essential; hypersensitivity reactions are uncommon but constitute a contraindication.atcddd.fhi+1youtube

Drug interactions and precautions

Because it remains within the gut lumen and can delay gastric emptying, methylcellulose may reduce or delay the absorption of concomitantly administered oral medicines if taken at the same time. Clinical interaction databases classify most interactions as minor to moderate in significance, and standard practice is to separate dosing of methylcellulose and other oral drugs by at least one to two hours.atcddd.fhi

Use in pregnancy and general toxicity

Methylcellulose has not been associated with teratogenicity in humans, although controlled pregnancy studies are lacking, and standard references recommend its use during pregnancy when the expected benefit outweighs any theoretical risk. Given its negligible systemic absorption and lack of known organ toxicity, it is generally preferred over stimulant laxatives when a non-pharmacological approach (dietary fibre, fluids, physical activity) is insufficient.kellymom+3

Lactation pharmacology and exposure

There are no quantitative data demonstrating excretion of methylcellulose into human milk; however, due to its non-absorbable nature and confinement to the gastrointestinal tract, clinically relevant levels in breast milk are not expected. General lactation pharmacology principles indicate that drugs with negligible maternal plasma concentrations, large molecular size and poor oral bioavailability in the infant result in very low relative infant doses and minimal risk.gpnotebook+3youtubekellymom

Lactation safety classifications

Specialised lactation references classify methylcellulose as “very low risk” or “compatible” with breastfeeding, indicating that it is not considered risky for the breastfed infant when used at therapeutic doses. These classifications typically recommend no need for routine interruption of breastfeeding, although standard clinical monitoring of the infant’s stool pattern and overall wellbeing remains good practice.e-lactation+2

Potential effects on the breastfed infant

Given the minimal expected transfer into milk and the lack of systemic absorption by the mother, direct pharmacological effects on the breastfed infant (such as diarrhoea, electrolyte disturbances or abdominal discomfort) are unlikely. If any change in infant stool frequency or consistency is observed temporally related to maternal methylcellulose use, clinicians may consider dose adjustment or switching to alternative non-pharmacological measures, although such reports are rare.drugsyoutubekellymom+1

Maternal considerations during lactation

For breastfeeding women, methylcellulose is often chosen as a first-line pharmacological option when dietary fibre and lifestyle measures do not sufficiently relieve postpartum constipation, including after perineal trauma or caesarean section. Adequate hydration, gradual titration of dose, and attention to overall fibre intake help optimise efficacy while minimising bloating or discomfort, and parallel use of other laxatives should be individualised based on clinical need.youtubekellymom+1

Clinical recommendations and monitoring

In lactating patients, methylcellulose can be used at the lowest effective dose for the shortest period compatible with achieving comfortable bowel movements, while encouraging non-drug measures. Clinicians should review concomitant oral therapies for potential absorption issues, counsel patients to space doses appropriately, and reassess therapy if constipation persists, worsens or is associated with alarm symptoms such as rectal bleeding, weight loss or severe abdominal pain.kellymom+2